BioMed X establishes its first US-based institute in New Haven with a new immunology research project in collaboration with AbbVie.
Demonstrates platform's ability to engineer mature human cardiac tissue and generate models of human heart disease starting from patient iPSCs
Scaling platform and building high-fidelity human-relevant datasets for in silico drug discovery
Applies Heart-on-a-chip Biowire™ Technology for Cardiac Disease Drug Discovery
